mobile
Healthcare
 
CII Media Releases
 
Move from “Health for All” to “Health by All” - Mr C K Mishra, Health Secretary : Govt to form an Expert Group to examine regulatory issues for Indian Vaccine industry
Nov 10, 2016

While addressing the inaugural session of the CII National Conference on Vaccine Industry in India “Reforms required for early accessibility, growth & sustained competitiveness” on 10th November 2016 at New Delhi, Mr CK Mishra, Secretary, Ministry of Health & Family Welfare, Government of India, said that the entire Indian Healthcare industry has to get involved for an effective healthcare delivery in India; and we must move from “Health for All” to “Health By All”, whereby the vaccine industry has a critical transformational role to play. Indian Government is fully geared to provide an enabling regulatory environment which would facilitate in creating a comprehensive national healthcare delivery system.

Further, Mr C K Mishra lauded the efforts of Indian vaccines players in leaving a mark on global landscape as leading supplier of vaccines to world, and said that it is encouraging to witness that there has never been an instance of shortage of vaccines in India primarily on account of successful implementation of our Mission Indradhanush.

Mr Mishra also stated that the domestic vaccines manufacturers should accord prime importance in meeting domestic demand; upscale R&D related work, and also take initiative in developing critical vaccines such as PCV and HPV. The Health Secretary said that the Government is committed to putting together resources for Mission Indradhanush. Besides, he stressed that both industry and government should continue nurturing the symbiotic relationship thereby taking vaccine industry to a higher level.

Mr KL Sharma, Joint Secretary, Ministry of Health & Family Welfare, Government of India called for the industry to submit specific recommendations within a fortnight, and assured a speedy response by the Government. Expressing optimism in capability of Indian vaccine industry, Mr Sharma said that this niche sector is going to be game changer, and Indian government is proud of its achievements.   

Responding to CII’s call for a Single Window System and ease in Clinical trial regulations, Dr G N Singh, Drug Controller General of India, Central Drugs Standard Control Organization, Government of India, announced formation of an Expert Group to examine the regulatory issues. This Expert group to be formed with CII would work towards a speedy resolution of issues in vaccines in time-bound manner without compromising critical aspects like quality, patient safety and patient management. Further, Dr Singh, appealed industry to chalk out a mechanism for Post Marketing Survey (PMS) so that hospitals will have a proper survey mechanism in place.

Earlier, Dr Rajesh Jain, Joint Managing Director, Panacea Biotech Pvt. Ltd, and Convener of the Conference, while delivering Welcome address, urged Government  to setup a Regulatory Innovation Cell” and also requested for minimize unnecessary paper work, maximize innovation, capitalize Mission Indradhanush by developing vaccines faster which are accessible for our country’s National Immunization Program in a timely manner.

Dr Suresh Jadhav, Executive Director, Serum Institute of India Ltd., said that this is a historical day when the senior officials of Health Ministry, regulators, and vaccine manufacturers, came together to address the issues to expedite the vaccines availability.

New Delhi

10 November 2016

Email to a friend   Print
Download CII App:
App Store Google Play